AtriCure (NASDAQ:ATRC) Director Sells 3,500 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,500 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director directly owned 14,015 shares of the company’s stock, valued at $538,456.30. The trade was a 19.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AtriCure Price Performance

Shares of NASDAQ:ATRC traded up $1.11 during trading on Friday, reaching $40.60. The stock had a trading volume of 108,527 shares, compared to its average volume of 800,970. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $43.18. The stock has a market cap of $2.07 billion, a PE ratio of 193.54 and a beta of 1.20. The business has a fifty day moving average price of $31.98 and a 200-day moving average price of $31.31.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ATRC. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. UBS Group lowered their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Hedge Funds Weigh In On AtriCure

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its position in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after buying an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after buying an additional 8,956 shares during the period. Jane Street Group LLC lifted its stake in AtriCure by 658.3% during the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares in the last quarter. Finally, Strs Ohio purchased a new position in AtriCure during the 1st quarter valued at about $158,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.